Drug intelligence / Profile preview

GLB-008

Development stage: Preclinical
Lead developer: GluBio Therapeutics
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

GLB-008 is a preclinical molecular glue degrader (MGD) developed by Hangzhou GluBio Pharmaceutical (GluBio Therapeutics) that targets Vav guanine nucleotide exchange factor 1 (VAV1). VAV1 is a critical signaling protein primarily expressed in hematopoietic cells, where it mediates T-cell and B-cell receptor signaling. By facilitating the recruitment of VAV1 to an E3 ubiquitin ligase complex, GLB-008 induces its ubiquitination and subsequent degradation via the proteasome. This targeted depletion of VAV1 is intended to suppress aberrant immune cell activation, providing a novel therapeutic strategy for the treatment of various autoimmune diseases.

Targets

VAV1 (Guanine nucleotide exchange factor VAV1)

Beyond the preview

Go deeper on GLB-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLB-008.

Explore the full profile